Spacavazza Paolo Leadiant B... Net Worth

The estimated Net Worth of Spacavazza Paolo Leadiant B... is at least $1.01 Million dollars as of 29 November 2017. Spacavazza B owns over 293,510 units of Soligenix Inc stock worth over $1,009,674 and over the last 7 years Spacavazza sold SNGX stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Spacavazza B SNGX stock SEC Form 4 insiders trading

Spacavazza has made over 1 trades of the Soligenix Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Spacavazza bought 293,510 units of SNGX stock worth $622,241 on 29 November 2017.

The largest trade Spacavazza's ever made was buying 293,510 units of Soligenix Inc stock on 29 November 2017 worth over $622,241. On average, Spacavazza trades about 293,510 units every 0 days since 2017. As of 29 November 2017 Spacavazza still owns at least 293,510 units of Soligenix Inc stock.

You can see the complete history of Spacavazza B stock trades at the bottom of the page.

Insiders trading at Soligenix Inc

Over the last 15 years, insiders at Soligenix Inc have traded over $502,220 worth of Soligenix Inc stock and bought 775,279 units worth $1,096,136 . The most active insiders traders include Randal Jintrexon Corp Kirk, Jerome B Zeldis, and Spacavazza Paolo Leadiant B.... On average, Soligenix Inc executives and independent directors trade stock every 115 days with the average trade being worth of $91,349. The most recent stock trade was executed by Richard Straube on 18 May 2022, trading 8,000 units of SNGX stock currently worth $4,000.

What does Soligenix Inc do?

soligenix, inc. is a late stage biopharmaceutical company committed to developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense. soligenix has two areas of focus: 1) a therapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as cutaneous t-cell lymphoma, oral mucositis, pediatric crohn's disease, acute radiation enteritis, and 2) a vaccines/biodefense segment to develop vaccines and therapeutics for military and civilian applications in the areas of ricin exposure, anthrax exposure, gastrointestinal acute radiation syndrome, and melioidosis.

Complete history of Spacavazza B stock trades at Soligenix Inc

Soligenix Inc executives and stock owners

Soligenix Inc executives and other stock owners filed with the SEC include:

• Dr. Christopher J. Schaber Ph.D.,
  Chairman, CEO & Pres
• Christopher Schaber,
  Chairman of the Board, President, Chief Executive Officer
• Dr. Oreola Donini Ph.D.,
  Sr. VP & Chief Scientific Officer
• Oreola Donini,
  Senior Vice President, Chief Scientific Officer
• Dr. Richard C. Straube M.D., MSc.,
  Sr. VP & Chief Medical Officer
• Jonathan L. Guarino CPA, CGMA,
  Sr. VP, CFO & Corp. Sec.
• Richard Straube,
  Senior Vice President and Chief Medical Officer
• Jonathan Guarino,
  Chief Financial Officer, Senior Vice President, Corporate Secretary
• Jerome Zeldis,
  Independent Director
• Robert Rubin,
  Independent Director
• Diane Parks,
  Independent Director
• Gregg Lapointe,
  Independent Director
• Richard L. Dunning,
  Exec. Officer
• Marco Maria Brughera,
  Director
• Keith L Brownlie,
  Director
• Karen R Krumeich,
  SVP and CFO
• Joseph Michael Warusz,
  VP of Finance/Acting CFO
• Randal Jintrexon Corp Kirk,
  
• Spacavazza Paolo Leadiant B...,
  
• Mark E. Pearson,
  Director
• Kevin Horgan,
  Senior VP; Chief Med Officer
• Virgil Thompson,
  Director
• Tamar D Howson,
  Director
• Management Llc Berman Ross ...,
  
• Robert N Brey,
  Chief Science Officer & Sr VP
• Paolo Cavazza,
  10% owner
• Evan Myrianthopoulos,
  CFO and Senior Vice Presient
• Brian L Hamilton,
  Chief Medical Officer & Sr VP
• Christopher P. Schnittker,
  VP-Admin., Controller
• Tau Finanziaria Spasigma Ta...,
  
• Claudio Cavazza,
  10% owner
• Timothy R. Cote,